DGM
Darwin Global Management Portfolio holdings
AUM
$2.38B
This Quarter Return
-3.85%
1 Year Return
+81.43%
3 Year Return
+6,053.69%
5 Year Return
–
10 Year Return
–
AUM
$511M
AUM Growth
+$511M
(+42%)
Cap. Flow
+$166M
Cap. Flow
% of AUM
32.45%
Top 10 Holdings %
Top 10 Hldgs %
99.69%
Holding
15
New
3
Increased
6
Reduced
3
Closed
3
Top Buys
| 1 |
BridgeBio Pharma
BBIO
|
$87.9M |
| 2 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$76.8M |
| 3 |
Fate Therapeutics
FATE
|
$34.4M |
| 4 |
Relay Therapeutics
RLAY
|
$27.1M |
| 5 |
MacroGenics
MGNX
|
$9.12M |
Top Sells
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$57.3M |
| 2 |
Sarepta Therapeutics
SRPT
|
$19.6M |
| 3 |
C4 Therapeutics
CCCC
|
$3.28M |
| 4 |
Immunovant
IMVT
|
$2.14M |
| 5 |
Stoke Therapeutics
STOK
|
$372K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
XLRN
1
DELISTED
Acceleron Pharma Inc.
XLRN
| $204M | 39.97% | 1,505,012 +566,522 | +60% | +$76.8M |
|
|
2
BridgeBio Pharma
BBIO
$9.89B
| $129M | 25.21% | 2,090,149 +1,427,191 | +215% | +$87.9M |
|
|
3
Fate Therapeutics
FATE
$120M
| $113M | 22.12% | 1,370,133 +417,286 | +44% | +$34.4M |
|
|
4
Relay Therapeutics
RLAY
$619M
| $27.1M | 5.3% | +782,471 | New | +$27.1M |
|
5
Arvinas
ARVN
$568M
| $9.29M | 1.82% | 140,511 +105,311 | +299% | +$6.96M |
|
|
6
MacroGenics
MGNX
$112M
| $9.12M | 1.78% | +286,195 | New | +$9.12M |
|
7
Generation Bio
GBIO
$40.4M
| $6.24M | 1.22% | 219,358 +22,167 | +11% | +$631K |
|
8
Keros Therapeutics
KROS
$618M
| $5.35M | 1.05% | +86,887 | New | +$5.35M |
|
|
9
C4 Therapeutics
CCCC
$185M
| $5.18M | 1.01% | 140,034 -88,561 | -39% | -$3.28M |
|
|
10
Immunovant
IMVT
$2.56B
| $1.06M | 0.21% | 65,849 -133,420 | -67% | -$2.14M |
|
|
INBX
11
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $998K | 0.2% | 49,709 +13,175 | +36% | +$265K |
|
12
Fulcrum Therapeutics
FULC
$351M
| $587K | 0.11% | 49,868 -11,445 | -19% | -$135K |
|
|
13
Sarepta Therapeutics
SRPT
$1.78B
| – | – | -114,900 | Closed | -$19.6M |
|
|
14
Stoke Therapeutics
STOK
$1.08B
| – | – | -6,000 | Closed | -$372K |
|
|
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – | -260,876 | Closed | -$57.3M |
|